Who is sponsoring NCT02713204?

NCT02713204 is sponsored by Regeneron Pharmaceuticals.

What drugs are being tested in NCT02713204?

Interventions in NCT02713204: REGN910-3, Intravitreal Aflibercept Injection (IAI).

What condition does NCT02713204 study?

NCT02713204 studies Neovascular Age-Related Macular Degeneration.

Is NCT02713204 still recruiting?

NCT02713204 is currently completed. Last updated 7 May 2019.

Are results published for NCT02713204?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2019-05-07 · How we verify

NCT02713204: ONYX

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection

Completed Phase 2 Results posted Last updated 7 May 2019

What this trial tests

Phase 2 trial testing REGN910-3 in Neovascular Age-Related Macular Degeneration in 365 participants. Completed in 3 October 2017.

Timeline

31 March 2016

Primary endpoint
3 October 2017

3 October 2017

Quick facts

Lead sponsor	Regeneron Pharmaceuticals
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	365
Start date	31 March 2016
Primary completion	3 October 2017
Estimated completion	3 October 2017
Sites	87 locations across United States

Drugs / interventions tested

REGN910-3 — full drug profile →
Intravitreal Aflibercept Injection (IAI) — full drug profile →

Conditions studied

Neovascular Age-Related Macular Degeneration — all drugs for Neovascular Age-Related Macular Degeneration →

Sponsor

Regeneron Pharmaceuticals — full company profile →

Who can join

50 and older, any sex, with Neovascular Age-Related Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Change From Baseline in Best Corrected Visual Acuity (BCVA) Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 12 Primary · At Week 12

Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at 4 meters. Best Corrected Visual Acuity (BCVA) score was measured using an eye chart and was reported as the number of letters read correctly at a testing distance of 4 meters using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. Change from baseline calculated by subtracti

Group	Value	95% CI
REGN910-3 (3 mg:2 mg)	5.2	± 10.51
REGN910-3 (6 mg:2 mg)	5.6	± 10.59
Aflibercept (IAI) 2 mg	5.4	± 9.85

Change From Baseline in Best Corrected Visual Acuity (BCVA) Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 36 Primary · At Week 36

Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at 4 meters. BCVA score was measured using an eye chart and was reported as the number of letters read correctly at a testing distance of 4 meters using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. Change from baseline calculated by subtracting baseline value from observed

Group	Value	95% CI
REGN910-3 (3 mg:2 mg)	5.9	± 11.95
REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q8	6.0	± 12.00
REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q12	6.4	± 12.24
Aflibercept 2(IAI) mg Q4 to Aflibercept (IAI) 2 mg Q8	6.9	± 12.49
Aflibercept (IAI) 2 mg Q4 to Aflibercept (IAI) 2 mg Q12	4.2	± 12.50
Aflibercept (IAI) 2 mg Q4 to REGN910-3 (6 mg:2 mg) Q8	2.9	± 12.16

Change From Baseline in Central Sub-field Retinal Thickness (CST) Measured by Spectral Domain Optical Coherence Tomography (SD-OCT) at Week 12 Secondary · At Week 12

Central Sub-field Retinal Thickness (CST) was assessed using Spectral Domain Optical Coherence Tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from baseline indicated improvement. Change from baseline calculated by subtracting baseline value from last observation carried forward (LOCF) post-baseline value at Week 12.

Group	Value	95% CI
REGN910-3 (3 mg:2 mg)	-182.2	± 172.73
REGN910-3 (6 mg:2 mg)	-200.0	± 152.82
Aflibercept (IAI) 2 mg	-178.6	± 138.85

Change From Baseline in Central Sub-field Retinal Thickness (CST) Measured by Spectral Domain Optical Coherence Tomography (SD-OCT) at Week 36 Secondary · At Week 36

CST was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from baseline indicated improvement. Change from baseline calculated by subtracting baseline value from LOCF post-baseline value at Week 36.

Group	Value	95% CI
REGN910-3 (3 mg:2 mg)	-174.6	± 165.22
REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q8	-216.6	± 187.40
REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q12	-181.3	± 148.71
Aflibercept (IAI) 2 mg Q4 to Aflibercept (IAI) 2 mg Q8	-198.4	± 155.72
Aflibercept (IAI) 2 mg Q4 to Aflibercept (IAI) 2 mg Q12	-169.7	± 129.74
Aflibercept (IAI) 2 mg Q4 to REGN910-3 (6 mg:2 mg) Q8	-187.3	± 161.72

Change From Baseline in Choroidal Neovascularization (CNV) Area at Week 12 Secondary · At Week 12

Choroidal neovascularization (CNV) was evaluated using fluorescein angiography (FA).CNV area values measured in square millimeters (mm\^2); lower values represent better outcomes.

Group	Value	95% CI
REGN910-3 (3 mg:2 mg)	-2.2	± 5.59
REGN910-3 (6 mg:2 mg)	-3.5	± 5.34
Aflibercept (IAI) 2 mg	-3.7	± 6.22

Change From Baseline in Choroidal Neovascularization (CNV) Area at Week 36 Secondary · At Week 36

Choroidal neovascularization (CNV) was evaluated using fluorescein angiography (FA).CNV area values measured in square millimeters (mm\^2); lower values represent better outcomes.

Group	Value	95% CI
REGN910-3 (3 mg:2 mg)	-3.7	± 5.04
REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q8	-4.1	± 6.09
REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q12	-4.9	± 5.58
Aflibercept (IAI) 2 mg Q4 to Aflibercept (IAI) 2 mg Q8	-4.3	± 6.55
Aflibercept (IAI) 2 mg Q4 to Aflibercept (IAI) 2 mg Q12	-5.1	± 5.60
Aflibercept (IAI) 2 mg Q4 to REGN910-3 (6 mg:2 mg) Q8	-5.3	± 5.19

Change From Baseline in Total Lesion Area at Week 12 Secondary · At Week 12

Total lesion area was evaluated using fluorescein angiography (FA). Lesion area values measured in square millimeters (mm\^2); lower values represent better outcomes.

Group	Value	95% CI
REGN910-3 (3 mg:2 mg)	-2.0	± 6.10
REGN910-3 (6 mg:2 mg)	-3.5	± 5.45
Aflibercept (IAI) 2 mg	-3.4	± 6.48

Change From Baseline in Total Lesion Area at Week 36 Secondary · At Week 36

Total lesion area was evaluated using fluorescein angiography (FA). Lesion area values measured in square millimeters (mm\^2); lower values represent better outcomes.

Group	Value	95% CI
REGN910-3 (3 mg:2 mg)	-3.0	± 5.91
REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q8	-3.9	± 5.79
REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q12	-4.7	± 5.35
Aflibercept (IAI) 2 mg Q4 to Aflibercept (IAI) 2 mg Q8	-3.9	± 6.67
Aflibercept (IAI) 2 mg Q4 to Aflibercept (IAI) 2 mg Q12	-4.7	± 5.43
Aflibercept (IAI) 2 mg Q4 to REGN910-3 (6 mg:2 mg) Q8	-5.3	± 5.20

Proportion of Participants With No Retinal and/or Subretinal Fluid at Week 12 Secondary · At Week 12

Retinal and/or subretinal fluid was assessed using intraretinal fluid (IRF) cystoid edema and subretinal fluid (SRF) in the center subfield on optical coherence tomography (OCT). If answers were "no" to both measurements, there was no retinal and/or subretinal fluid (Dry); if "yes" to any of the 2 measurements, there was retinal and/or subretinal fluid (Not Dry); other than the previous 2 cases, retinal and/or subretinal fluid was undetermined.

Group	Value	95% CI
REGN910-3 (3 mg:2 mg)	0.49
REGN910-3 (6 mg:2 mg)	0.51
Aflibercept (IAI) 2 mg	0.44

Proportion of Participants With No Retinal and/or Subretinal Fluid From Baseline Through Week 36 Secondary · Baseline through Week 36

Retinal and/or subretinal fluid was assessed using intraretinal fluid (IRF) cystoid edema and subretinal fluid (SRF) in the center subfield on OCT. If answers were "no" to both measurements, there was no retinal and/or subretinal fluid (Dry); if "yes" to any of the 2 measurements, there was retinal and/or subretinal fluid (Not Dry); other than the previous 2 cases, retinal and/or subretinal fluid was undetermined.

Group	Value	95% CI
REGN910-3 (3 mg:2 mg)	0.54
REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q8	0.49
REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q12	0.53
Aflibercept (IAI) 2 mg Q4 to Aflibercept (IAI) 2 mg Q8	0.42
Aflibercept (IAI) 2 mg Q4 to Aflibercept (IAI) 2 mg Q12	0.53
Aflibercept (IAI) 2 mg Q4 to REGN910-3 (6 mg:2 mg) Q8	0.47

Time to No Retinal and/or Subretinal Fluid Through Week 36 Secondary · Baseline through Week 36

Kaplan-Meier estimated time to no retinal and/or subretinal fluid through week 36 (days). Retinal and/or subretinal fluid was assessed using intraretinal fluid (IRF) cystoid edema and subretinal fluid (SRF). If answers were "no" to both measurements, there was no retinal and/or subretinal fluid (Dry); if "yes" to any of the 2 measurements, there was retinal and/or subretinal fluid (Not Dry); other than the previous 2 cases, retinal and/or subretinal fluid was undetermined.

Group	Value	95% CI
REGN910-3 (3 mg:2 mg)	105.6	± 11.06
REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q8	80.9	± 9.02
REGN910-3 (6 mg:2 mg) Q4 to REGN910-3 (6 mg:2 mg) Q12	84.9	± 8.01
Aflibercept (IAI) 2 mg Q4 to Aflibercept (IAI) 2 mg Q8	106.4	± 11.04
Aflibercept (IAI) 2 mg Q4 to Aflibercept (IAI) 2 mg Q12	96.5	± 11.27
Aflibercept (IAI) 2 mg Q4 to REGN910-3 (6 mg:2 mg) Q8	107.1	± 10.05

Adverse events — posted to ClinicalTrials.gov

Time frame: Timeframe for AE reporting. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

REGN910-3 3 mg:2 mg

Serious: 11/60 (18%)

Deaths: 1/60

REGN910-3 6 mg:2 mg

Serious: 20/122 (16%)

Deaths: 2/122

IAI 2 mg

Serious: 30/183 (16%)

Deaths: 7/183

IAI 2mg to REGN910-3

Serious: 8/58 (14%)

Deaths: 3/58

Serious adverse events (64 terms)

Reaction	System	REGN910-3 3 mg:2 mg	REGN910-3 6 mg:2 mg	IAI 2 mg	IAI 2mg to REGN910-3
Pneumonia	Infections and infestations	—	—	—	—
Acute myocardial infarction	Cardiac disorders	—	—	—	—
Cellulitis	Infections and infestations	—	—	—	—
Sepsis	Infections and infestations	—	—	—	—
Fall	Injury, poisoning and procedural complications	—	—	—	—
Hip fracture	Injury, poisoning and procedural complications	—	—	—	—
Rib fracture	Injury, poisoning and procedural complications	—	—	—	—
Metastases to bone	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—	—
Cerebrovascular accident	Nervous system disorders	—	—	—	—
Chronic kidney disease	Renal and urinary disorders	—	—	—	—
Chronic obstructive pulmonary disease	Respiratory, thoracic and mediastinal disorders	—	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—	—
Atrioventricular block	Cardiac disorders	—	—	—	—
Cardiac failure	Cardiac disorders	—	—	—	—
Cardiac failure congestive	Cardiac disorders	—	—	—	—
Cardio-Respiratory arrest	Cardiac disorders	—	—	—	—
Coronary artery disease	Cardiac disorders	—	—	—	—
Pericardial effusion	Cardiac disorders	—	—	—	—
Supraventricular tachycardia	Cardiac disorders	—	—	—	—
Vertigo	Ear and labyrinth disorders	—	—	—	—
Corneal oedema	Eye disorders	—	—	—	—
Dry age-related macular degeneration	Eye disorders	—	—	—	—
Iritis	Eye disorders	—	—	—	—
Macular hole	Eye disorders	—	—	—	—
Retinal degeneration	Eye disorders	—	—	—	—

Other adverse events (9 terms — click to expand)

Reaction	System	REGN910-3 3 mg:2 mg	REGN910-3 6 mg:2 mg	IAI 2 mg	IAI 2mg to REGN910-3
Hypertension	Vascular disorders	—	—	—	—
Retinal haemorrhage	Eye disorders	—	—	—	—
Dry eye	Eye disorders	—	—	—	—
Vitreous detachment	Eye disorders	—	—	—	—
Urinary tract infection	Infections and infestations	—	—	—	—
Neovascular age-related macular degeneration	Eye disorders	—	—	—	—
Atrial fibrillation	Cardiac disorders	—	—	—	—
Upper respiratory tract infection	Infections and infestations	—	—	—	—
Osteoarthritis	Musculoskeletal and connective tissue disorders	—	—	—	—

Most-reported serious reactions: Pneumonia, Acute myocardial infarction, Cellulitis, Sepsis, Fall, Hip fracture, Rib fracture, Metastases to bone.

Data from ClinicalTrials.gov NCT02713204 adverse events section.

Sponsor's own description

The primary objective of the study is to compare the efficacy of intravitreal (IVT)-administered REGN910-3 compared to intravitreal aflibercept injection (IAI).

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Retinal and choroidal angiogenesis: a review of new targets.
Cabral T, Mello LGM, Lima LH, Polido J, et al · · 2017 · cited 114× · PMID 28835854 · DOI 10.1186/s40942-017-0084-9
Recent Advances in Age-Related Macular Degeneration Therapies.
Fabre M, Mateo L, Lamaa D, Baillif S, et al · · 2022 · cited 68× · PMID 36014339 · DOI 10.3390/molecules27165089
Sustained delivery of acriflavine from the suprachoroidal space provides long term suppression of choroidal neovascularization.
Hackett SF, Fu J, Kim YC, Tsujinaka H, et al · · 2020 · cited 38× · PMID 32172031 · DOI 10.1016/j.biomaterials.2020.119935
The Role of Angiopoietins in Neovascular Diabetes-Related Retinal Diseases.
Collazos-Alemán JD, Gnecco-González S, Jaramillo-Zarama B, Jiménez-Mora MA, et al · · 2022 · cited 23× · PMID 36331711 · DOI 10.1007/s13300-022-01326-9
Intravitreal Nesvacumab (Anti-Angiopoietin-2) Plus Aflibercept in Neovascular AMD: Phase 2 ONYX Randomized Trial.
Heier JS, Ho AC, Boyer DS, Csaky K, et al · · 2023 · cited 10× · PMID 37008402 · DOI 10.1177/24741264221126061
Communication Of Cancer Cells And Lymphatic Vessels In Cancer: Focus On Bladder Cancer.
Wu ZS, Ding W, Cai J, Bashir G, et al · · 2019 · cited 5× · PMID 31632067 · DOI 10.2147/ott.s219111
Rethinking the potential and necessity of drug delivery systems in neovascular age-related macular degeneration therapy.
Huang X, Zhang L, Fu Y, Zhang M, et al · · 2023 · cited 3× · PMID 37288355 · DOI 10.3389/fbioe.2023.1199922

Verify or expand the search:

Other trials of REGN910-3

Trials testing the same drug.

NCT02712008 — Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatm · Phase 2 · completed

Other recruiting trials for Neovascular Age-Related Macular Degeneration

Currently open trials in the same condition.

NCT06491914 — A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related · Phase 3 · active not recruiting
NCT06223958 — Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects Wi · Phase 3 · active not recruiting
NCT03683251 — Extension Study for the Port Delivery System With Ranibizumab (Portal) · Phase 3 · recruiting

Other Regeneron Pharmaceuticals trials

Trials by the same sponsor.

NCT07428369 — A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) · Phase 2, PHASE3 · not yet recruiting
NCT07526116 — A First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a Single Dose of REGN22044 in Healthy Adul · Phase 1 · not yet recruiting
NCT07527923 — First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis · Phase 1 · not yet recruiting
NCT07527910 — A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD · Phase 2 · not yet recruiting
NCT07477704 — A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemi · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02713204 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Regeneron Pharmaceuticals
Last refreshed: 7 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02713204.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing